This reflected the potential effects of ER+/− status accuracy estimated by ESR1 expression, lymph-node status, co-existence of other dominant modulator genes in ovarian cancer, expression measurement (log-transform or not, RPKM or TPM, etc.), and characteristics of sample population on ER modulation as well as our model (see the Supplementary Discussion section). The gene discussed is ESR1; the disease is ovarian carcinoma.